All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00053296" target="_blank" >RIV/00216224:14110/11:00053296 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11110/11:10110 RIV/00064165:_____/11:10110

  • Result on the web

    <a href="http://dx.doi.org/10.1586/ERA.11.38" target="_blank" >http://dx.doi.org/10.1586/ERA.11.38</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1586/ERA.11.38" target="_blank" >10.1586/ERA.11.38</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis

  • Original language description

    Prophylactic salpingo-oophorectomy is currently the only effective strategy available for decreasing ovarian cancer risk in BRCA1/2 mutation carriers. Significantly decreased risk of ovarian cancer associated with the use of combined oral contraceptives(COCs) was shown in the general population, which could be an alternative approach for those who do not accept risk-reducing surgery. Cohort, case?control and case?case studies published in English up to December 2009 reporting the association of ovarianor breast cancer risk with the use of COCs and presenting BRCA status were selected for meta-analysis. Meta-analysis of three case?control studies showed a significant risk reduction of ovarian cancer in BRCA1/2 mutation carriers who were associated with any past COC use and significant trend by duration of COC use (OR: 0.95; 95% CI: 0.93?0.97). No significant increase in breast cancer risk associated with COC use has been found in case?control studies in BRCA1 (OR: 1.08; p = 0.250), in

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

    <a href="/en/project/GP301%2F08%2FP103" target="_blank" >GP301/08/P103: Promoter methylation analysis of the genes downstream of BRCA1 and BRCA1 - comparison of methylation profiles in mutation carriers and non-carriers</a><br>

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2011

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Expert Review of Anticancer Therapy

  • ISSN

    1473-7140

  • e-ISSN

  • Volume of the periodical

    11

  • Issue of the periodical within the volume

    8

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    11

  • Pages from-to

    1197-1207

  • UT code for WoS article

    000294978600012

  • EID of the result in the Scopus database